ILMN Sold off big time and fell lower, similar to ALGN
Put Spread $282.5/252.5 EXP is September 27th
30 points wide and cost was $9.13
Market continues to sell off and it could move lower to EMA 200 where it may bounce.
Exit 1 underlying price of $252.5 and max profit will be $1050 Time looks good and my preference for this move is around 45 days.
Max loss...
After bad guidance and downgrades, $ILMN was destined to fall. My theory for initiating a swing trade is the selling was too overdone. This is not a long-term "long" but an idea for a short-term "long". I think it is very likely to recover to the 200 EMA (purple line) but watch there is a daily trend line (black line) which will likely be strong resistance too....
The major damage has been done in NASDAQ:ILMN but further damage is very possible, those that bought the dip today got no reward and will have a anxious wait on monday to see if more downgrades will follow. It will take some time before investors will rush back into the stock as it still carries a very hefty valuation.
The genetics company expects to report...
ILMN had a false breakout as traders took profits pre earnings. Post earnings we may see a recovery. A break below the pin bar would negate the thesis.
Bullish to neutral.
I placed this spread earlier today. This stock has been lagging yet bullish move is strong for now, this is the reason for a bull put spread, so I can use some of this bullish move, but also if it retraces I can still profit.
Illumina, Inc. (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc. (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations. Core Illumina's products and services serve customers in the research, clinical and applied markets, and enable the adoption of a range of genomic solutions. The Company's portfolio of integrated systems, consumables and analysis tools addresses the range of genomic complexity, price points, and throughput, enabling customers to select the solution for their research or clinical challenge. The Company provides reproductive-health solutions, including noninvasive prenatal testing (NIPT), preimplantation genetic screening and diagnosis, and neonatal and genetic health testing.
This website uses cookies to ensure you get the best experience on our website. To learn more about cookies, including how to control cookies, please read our Cookies Policy.
ILMN
